Skip to main content
Erschienen in: Medical Oncology 4/2017

01.04.2017 | Original Paper

Chemotherapy for ovarian cancer in the Netherlands: a population-based study on treatment patterns and outcomes

verfasst von: E. Houben, H. G. M. van Haalen, W. Sparreboom, J. A. Overbeek, N. P. M. Ezendam, J. M. A. Pijnenborg, J. L. Severens, M. P. P. van Herk-Sukel

Erschienen in: Medical Oncology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Information on treatment patterns for ovarian cancer (OC) is limited. The aim of this study was to describe current patterns of chemotherapy and other systemic treatments for OC in the Netherlands and evaluate survival outcomes following subsequent lines of treatment. Data from the Eindhoven Cancer Registry, including on newly diagnosed cancer patients, were linked to the PHARMO Database Network, including information on in- and out-patient drug use. Patients diagnosed with OC between January 2000 and December 2010 were selected. An algorithm was used to identify separate lines of treatment. Data were studied descriptively. Detailed data on systemic drug use were available for 261 patients (17%) with OC. In first-line treatment, 87% of the patients (227/261) received platinum-based chemotherapy. Of the 161 patients receiving second-line treatment, 101 patients (63%) received platinum-based chemotherapy. In third line, this was 51% (53/103). The median number of treatment lines received by patients was two (interquartile range 1–3), and eight or more lines of chemotherapy were identified for 12 patients. Median survival from diagnosis onwards was 47 months from the end of first-line treatment, median survival was 32 months, and from the end of second-line treatment, it was 14 months. Predominantly beyond second-line treatment, there is much variety in treatment patterns with chemotherapy for OC. Although uncertainty remains regarding the desirability of this observed treatment variation, there seems a need for detailed clinical guidance, assuring that physicians can properly choose the most suitable treatment for each patient.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat van Altena AM, Karim-Kos HE, de Vries E, et al. Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands. Gynecol Oncol. 2012;125(3):649–54.CrossRefPubMed van Altena AM, Karim-Kos HE, de Vries E, et al. Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands. Gynecol Oncol. 2012;125(3):649–54.CrossRefPubMed
3.
Zurück zum Zitat Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;Suppl 6:vi24–32. Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;Suppl 6:vi24–32.
4.
Zurück zum Zitat Rutten MJ, Boldingh JH, Schuit E, et al. Development and internal validation of a prognostic model for survival after debulking surgery for epithelial ovarian cancer. Gynecol Oncol. 2014;135(1):13–8.CrossRefPubMed Rutten MJ, Boldingh JH, Schuit E, et al. Development and internal validation of a prognostic model for survival after debulking surgery for epithelial ovarian cancer. Gynecol Oncol. 2014;135(1):13–8.CrossRefPubMed
5.
Zurück zum Zitat Commissie Richtlijnen Gynaecologische Oncologie, Integraal Kankercentrum Nederland. National Guideline Epithelial Ovariancarcinoma, 2012. http://www.oncoline.nl. Accessed Sep 2014. Commissie Richtlijnen Gynaecologische Oncologie, Integraal Kankercentrum Nederland. National Guideline Epithelial Ovariancarcinoma, 2012. http://​www.​oncoline.​nl. Accessed Sep 2014.
6.
Zurück zum Zitat Fung-Kee-Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007;14(5):195–208.CrossRefPubMedPubMedCentral Fung-Kee-Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007;14(5):195–208.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Vencken PM, Reitsma W, Kriege M, et al. Outcome of BRCA1-compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands. Ann Oncol. 2013;24(8):2036–42.CrossRefPubMed Vencken PM, Reitsma W, Kriege M, et al. Outcome of BRCA1-compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands. Ann Oncol. 2013;24(8):2036–42.CrossRefPubMed
8.
Zurück zum Zitat van Herk-Sukel MP, van de Poll-Franse LV, Lemmens VE, et al. New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J Cancer. 2010;46(2):395–404.CrossRefPubMed van Herk-Sukel MP, van de Poll-Franse LV, Lemmens VE, et al. New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J Cancer. 2010;46(2):395–404.CrossRefPubMed
9.
Zurück zum Zitat Herings RMC, Pedersen L. Pharmacy-based Medical Record LInkage Systems. In: Strom BL, Kimmel SE, Hennessy, editors. Pharmacoepidemiology. 5th ed. Blackwell: Oxford; 2012. p. 270–86.CrossRef Herings RMC, Pedersen L. Pharmacy-based Medical Record LInkage Systems. In: Strom BL, Kimmel SE, Hennessy, editors. Pharmacoepidemiology. 5th ed. Blackwell: Oxford; 2012. p. 270–86.CrossRef
10.
Zurück zum Zitat van Herk-Sukel MP, Lemmens VE, Poll-Franse LV, et al. Record linkage for pharmacoepidemiological studies in cancer patients. Pharmacoepidemiol Drug Saf. 2012;21(1):94–103.CrossRefPubMed van Herk-Sukel MP, Lemmens VE, Poll-Franse LV, et al. Record linkage for pharmacoepidemiological studies in cancer patients. Pharmacoepidemiol Drug Saf. 2012;21(1):94–103.CrossRefPubMed
11.
Zurück zum Zitat Seal B, Shermock KM, Asche CV, et al. The implications of using a 30-, 60-, or 90-day gap in treatment to specify lines of care in gastric cancer treatment. Value Health. 2015;18(3):A2.CrossRef Seal B, Shermock KM, Asche CV, et al. The implications of using a 30-, 60-, or 90-day gap in treatment to specify lines of care in gastric cancer treatment. Value Health. 2015;18(3):A2.CrossRef
12.
Zurück zum Zitat Vencken PM, Kriege M, Hoogwerf D, et al. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol. 2011;22(6):1346–52.CrossRefPubMed Vencken PM, Kriege M, Hoogwerf D, et al. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann Oncol. 2011;22(6):1346–52.CrossRefPubMed
13.
Zurück zum Zitat Barlin JN, Yu C, Hill EK, et al. Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer. Gynecol Oncol. 2012;125(1):25–30.CrossRefPubMed Barlin JN, Yu C, Hill EK, et al. Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer. Gynecol Oncol. 2012;125(1):25–30.CrossRefPubMed
14.
Zurück zum Zitat Previs RA, Bevis KS, Huh W, et al. A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy. Gynecol Oncol. 2014;132(3):531–6.CrossRefPubMed Previs RA, Bevis KS, Huh W, et al. A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy. Gynecol Oncol. 2014;132(3):531–6.CrossRefPubMed
15.
Zurück zum Zitat Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361(9375):2099–106.CrossRefPubMed Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361(9375):2099–106.CrossRefPubMed
16.
Zurück zum Zitat Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699–707.CrossRefPubMed Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699–707.CrossRefPubMed
17.
Zurück zum Zitat Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012;107(4):588–91.CrossRefPubMedPubMedCentral Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012;107(4):588–91.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Aghajanian C, Goff BA, Nycum LR, et al. Final analysis of overall survival in OCEANS, a randomised phase III trial of gemcitabine, carboplatin, and bevacizumab followed by bevacizumab until disease progression in patients with platinum-sensitive recurrent ovarian cancer. 2014-03-22 to 2014-03-25; Tampa, FL, United States. Gynecol Oncol. 2014;133(Suppl. 1):57.CrossRef Aghajanian C, Goff BA, Nycum LR, et al. Final analysis of overall survival in OCEANS, a randomised phase III trial of gemcitabine, carboplatin, and bevacizumab followed by bevacizumab until disease progression in patients with platinum-sensitive recurrent ovarian cancer. 2014-03-22 to 2014-03-25; Tampa, FL, United States. Gynecol Oncol. 2014;133(Suppl. 1):57.CrossRef
19.
Zurück zum Zitat Rustin GJ, Vergote I, Eisenhauer E, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419–23.CrossRefPubMed Rustin GJ, Vergote I, Eisenhauer E, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419–23.CrossRefPubMed
Metadaten
Titel
Chemotherapy for ovarian cancer in the Netherlands: a population-based study on treatment patterns and outcomes
verfasst von
E. Houben
H. G. M. van Haalen
W. Sparreboom
J. A. Overbeek
N. P. M. Ezendam
J. M. A. Pijnenborg
J. L. Severens
M. P. P. van Herk-Sukel
Publikationsdatum
01.04.2017
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 4/2017
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-017-0901-x

Weitere Artikel der Ausgabe 4/2017

Medical Oncology 4/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.